Compare Brilacidin (evidence C) and LL-37 (evidence D) on mechanism, clinical status, safety, and dosing.
Brilacidin (PMX-30063) is a synthetic small-molecule defensin-mimetic (MW ~564 g/mol) developed by Innovation Pharmaceuticals (formerly Cellceutix). It is a…
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid cationic peptide (sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) with…
Full profiles: Brilacidin, LL-37.